Synthesis, crystal structure analysis, and pharmacological characterization of disila-bexarotene, a disila-analogue of the RXR-selective retinoid agonist bexarotene

被引:56
作者
Daiss, JO
Burschka, C
Mills, JS
Montana, JG
Showell, GA
Fleming, I
Gaudon, C
Ivanova, D
Gronemeyer, H
Tacke, R
机构
[1] Univ Wurzburg, Inst Anorgan Chem, D-97074 Wurzburg, Germany
[2] ULP, CNRS, INSERM, Cambridge CB4 0GP, England
关键词
D O I
10.1021/om040143k
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
Twofold sila-substitution (C/Si exchange) in the saturated ring of the tetrahydronaphthalene skeleton of the RXR-selective retinoid agonist bexarotene (1a) leads to disilabexarotene (1b). Compound 1b was synthesized in a multistep synthesis, starting from 1,2-bis(chlorodimethylsilyl)ethane. The identity of 1b was established by elemental analyses and multinuclear NMR studies, and the C/Si analogues 1a and 1b (and an intermediate in the synthesis of 1b) were structurally characterized by single-crystal X-ray diffraction. Furthermore, 1a and 1b were studied for their interaction with retinoid X receptors. Although the twofold sila-substitution of la resulted in significant differences in the molecular structures of 1a and 1b, disila-bexarotene (1b) was shown to be a highly potent RXR agonist.
引用
收藏
页码:3192 / 3199
页数:8
相关论文
共 60 条
[1]   The promise of retinoids to fight against cancer [J].
Altucci, L ;
Gronemeyer, H .
NATURE REVIEWS CANCER, 2001, 1 (03) :181-193
[2]  
Bains W, 2003, CURR OPIN DRUG DISC, V6, P526
[3]  
Bedikian AY, 2000, ONCOL REP, V7, P883
[4]  
Boehm M.F., 1993, USA Patent, Patent No. [WO9321146, 9321146]
[5]   DESIGN AND SYNTHESIS OF POTENT RETINOID-X RECEPTOR-SELECTIVE LIGANDS THAT INDUCE APOPTOSIS IN LEUKEMIA-CELLS [J].
BOEHM, MF ;
ZHANG, L ;
ZHI, L ;
MCCLURG, MR ;
BERGER, E ;
WAGONER, M ;
MAIS, DE ;
SUTO, CM ;
DAVIES, PJA ;
HEYMAN, RA ;
NADZAN, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (16) :3146-3155
[6]   SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF NOVEL RETINOID-X RECEPTOR-SELECTIVE RETINOIDS [J].
BOEHM, MF ;
ZHANG, L ;
BADEA, BA ;
WHITE, SK ;
MAIS, DE ;
BERGER, E ;
SUTO, CM ;
GOLDMAN, ME ;
HEYMAN, RA .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (18) :2930-2941
[7]   Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications [J].
Bourguet, W ;
Germain, P ;
Gronemeyer, H .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (10) :381-388
[8]   Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma [J].
Breneman, D ;
Duvic, M ;
Kuzel, T ;
Yocum, R ;
Truglia, J ;
Stevens, VJ .
ARCHIVES OF DERMATOLOGY, 2002, 138 (03) :325-332
[9]  
Camacho LH, 2003, J BIOL REG HOMEOS AG, V17, P98
[10]   RAR-SPECIFIC AGONIST/ANTAGONISTS WHICH DISSOCIATE TRANSACTIVATION AND AP1 TRANSREPRESSION INHIBIT ANCHORAGE-INDEPENDENT CELL-PROLIFERATION [J].
CHEN, JY ;
PENCO, S ;
OSTROWSKI, J ;
BALAGUER, P ;
PONS, M ;
STARRETT, JE ;
RECZEK, P ;
CHAMBON, P ;
GRONEMEYER, H .
EMBO JOURNAL, 1995, 14 (06) :1187-1197